團隊介紹Our Team

精實核心團隊,結合集團資源與外部專業網絡的執行模式 A Lean Core Team, Backed by Group Resources and an External Execution Network

台基核以精實團隊聚焦核心研發策略:研發人員專注於序列演算法設計與新藥開發策略規劃,臨床前試驗執行委由專業 CRO 夥伴進行,並由母公司泰宗生技集團同仁提供 CMC、臨床、行政與財務等職能之人力支援,同時與學研機構深度合作,以資本效率最大化之方式推進核酸新藥開發進程。 CoGentide operates with a lean team focused on core R&D strategy: our researchers concentrate on ASO sequence design and drug development strategy, preclinical testing is carried out through professional CRO partners, and functions such as CMC, clinical, administrative, and finance are supported by colleagues at our parent company, TCM Biotech International Corp.

台基核核心團隊實驗室討論

核心科學團隊Core Science Team

研發人員由具備豐富業界新藥開發經驗之同仁帶領,成員具備紮實之分子生物學與藥物開發專業背景,主責候選核酸新藥之篩選策略規劃與臨床前試驗執行監督。 Our research team is led by a colleague with extensive industry drug development experience, supported by researchers with strong backgrounds in molecular biology and drug development. The team is responsible for candidate screening strategy and oversight of preclinical execution.

集團資源Group Resources

台基核為泰宗生技集團旗下子公司,於 CMC、臨床開發、行政與財務等職能面向,由集團同仁提供人力支援與專業經驗。 CoGentide is a subsidiary of TCM Biotech International Corp. Colleagues from the group provide personnel support and expertise across functions such as CMC, clinical development, administration, and finance.

外部協作網絡External Collaboration Network

臨床前試驗委由專業 CRO 夥伴執行,並與台大生命科學院、台大醫學院及長庚大學等學研機構合作,共同支持核酸新藥開發之各階段驗證工作。 Preclinical testing is carried out through professional CRO partners, and we collaborate with academic partners such as National Taiwan University's College of Life Science, College of Medicine, and Chang Gung University.

與我們展開合作對話Let's Start a Conversation

歡迎與我們的團隊聯繫,進一步了解台基核的核酸新藥開發進程。Get in touch with our team to learn more about CoGentide's nucleic acid drug development.

聯絡我們Contact Us